A pedestrian passes a Nestle SA logo at the Nescafe factory, operated by Nestle SA, in Tutbury, U.K., on Thursday, Aug. 23, 2018.
Simon Dawson | Bloomberg | Getty Images
Nestle said it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own, adding a potential blockbuster to its health science portfolio.
The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million Nestle had already invested in Aimmune, Nestle said in a statement.
No comments:
Post a Comment